CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-14). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2524 · Search date 2026-08-14 · Methodology v0.7

Active management of the third stage of labor,
does it really help with Reduced postpartum hemorrhage of at least 500 mL versus physiological or expectant management?

30-Second Summary
B
Evidence Grade B · 76 · Safety caution
Bundled active management substantially reduced postpartum hemorrhage of at least 500 mL in two large trials.
Active management can increase nausea, vomiting, and blood pressure, particularly with historical ergometrine-containing regimens. A trained maternity team should account for drug contraindications, bleeding risk, cord-clamping timing, and maternal preferences.
What the
research shows
The grade is B. Postpartum hemorrhage of at least 500 mL occurred in 50/846 versus 152/849 in Bristol and 51/748 versus 126/764 in Hinchingbrooke. Absolute risk fell by about 12 and 10 percentage points, a large and consistent effect. D. R. Elbourne participated in both trials, so they were not counted as replication by fully independent investigator groups, giving B with 76 points.
What the
ads claim
Active management is not one drug or maneuver; it is a bundle of uterotonic use, cord handling, and placental delivery. Evidence for the bundle cannot be split into separate proof for each drug, traction technique, or immediate cord clamping.
*

Useful facts when choosing a product

  • Bristol usually used 5 units oxytocin plus 0.5 mg ergometrine, cord clamping within 30 seconds, and controlled cord traction.
  • Hinchingbrooke used a prophylactic uterotonic within two minutes, immediate cord clamping and cutting, and controlled traction or maternal effort.
  • The historical bundles may differ from modern management that incorporates delayed cord clamping.
  • No duplicate ingredient-outcome verdict or reuse of either PMID/DOI pair was found in the existing list.
Gap Measurement · Verdict 2524 · B 76
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Bristol assigned 1,695 women, 846 versus 849, using correspondingly numbered sealed opaque envelopes. Active management usually included oxytocin plus ergometrine, cord clamping within 30 seconds, and controlled cord traction. Clinical blood-loss assessment was unblinded, although allocation concealment was adequate. Hinchingbrooke assigned 1,512 low-risk women, 748 versus 764, analyzed them by intention to treat, and objective blood-loss measures confirmed the result. ISRCTN63422923 was registered on January 23, 2004, after 1993-95 recruitment and 1998 publication, so it was retrospective despite the registry display. Both trials had public or nonprofit funding, but D. R. Elbourne in Bristol and D. Elbourne in Hinchingbrooke are the same investigator, Diana Elbourne. This overlap prevents fully independent replication, so axis 2 remains R1.

02

Why this is classified as B (76)

Two publicly funded trials enrolling more than 1,500 women each reduced a hard hemorrhage event by about 10 to 12 points. The common investigator prevented independent-replication credit, and unblinded clinical blood-loss assessment remained a limitation, giving B with 76 points.

Counterpoint. This verdict compares historical active-management bundles with physiological or expectant management in hospital vaginal birth. Cesarean delivery, home birth, comparisons among uterotonics, and omission of controlled cord traction are separate questions.

Rejudgment record. Cross-check applied — We cross-checked randomized and analyzed counts, hemorrhage events, bundle components, public funding, shared investigators, and the actual ISRCTN registration date.

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (B).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Bundled active management of the third stage reduces postpartum hemorrhage of at least 500 mL.BTwo large trials found absolute risk reductions of about 10 to 12 percentage points.
Early cord clamping alone causes the reduction in postpartum hemorrhage.?The trials also changed uterotonic use and placental traction, so the isolated effect of early clamping was not estimated.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Single-hospital individually randomized controlled trial849Additional WHO Maternity and Child Division funds and DHSS support for the National Perinatal Epidemiology UnitPostpartum hemorrhage defined as clinically estimated blood loss of at least 500 mL50/846 (5.9%) versus 152/849 (17.9%); active-versus-physiological RR 0.33 (95% CI 0.24-0.45)Large publicly and nonprofit funded positive hemorrhage trial
Study 2Individually randomized 2-by-2 factorial trial in low-risk women764Public Health and Operational Research Committee of the Anglia and Oxford Regional Health Authority and Department of Health support for the National Perinatal Epidemiology UnitPostpartum hemorrhage defined as estimated blood loss of at least 500 mL within 24 hours51/748 (6.8%) versus 126/764 (16.5%); active-versus-expectant RR 0.41 (95% CI 0.30-0.56), P<.0001Large publicly funded trial in the same direction but with a shared investigator
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-14).

Prendiville WJ, Harding JE, Elbourne DR, Stirrat GM. The Bristol third stage trial: active versus physiological management of third stage of labour. BMJ. 1988;297(6659):1295-1300. PMID: 3144366. DOI: 10.1136/bmj.297.6659.1295.
checked
Rogers J, Wood J, McCandlish R, Ayers S, Truesdale A, Elbourne D. Active versus expectant management of third stage of labour. Lancet. 1998;351(9104):693-699. PMID: 9504513. DOI: 10.1016/S0140-6736(97)09409-9. ISRCTN63422923.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-14 · Corrections: none

Cite this verdict

Active management of the third stage of labor x prevention of postpartum hemorrhage Evidence Grade B card
[Chamgap] Active management of the third stage of labor x prevention of postpartum hemorrhage — Evidence Grade B·76. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/active-management-third-stage-labour-postpartum-haemorrhage/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.